Why Bluebird Bio (BLUE) Stock Hit a One-Year High Today

NEW YORK (TheStreet) -- Bluebird Bio  (BLUE) surged to a 52-week high of $41.77 on Monday after the company reported positive results on Saturday from its gene therapy for the blood disorder beta-thalassemia.

The company announced that two patients with the blood disorder were able to cease blood transfusions after one treatment with BlueBird's experimental gene therapy called LentiGlobin, which replaces the defective gene with a fully functional one.

The stock was up 34.73% to $35.15 at 11:56 a.m. More than 4.2 million shares had changed hands, compared to the average volume of 239,356.

Must Read: Bluebird Bio Higher on Strong Gene Therapy Study Results

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

BLUE Price Chart

BLUE Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers